W
IPXL

Wealthfront’s Impax Laboratories, Inc. IPXL Stock Holding History

Wealthfront’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-215
Closed -$8K – 1263
2015
Q3 		$8K Sell
215
-36
-14% -$1.62K ﹤0.01% 1030
2015
Q2 		$12K Buy
251
+112
+81% +$5.32K ﹤0.01% 791
2015
Q1 		$7K Buy
139
+138
+13,800% +$5.49K ﹤0.01% 725
2014
Q4 		$0 Buy
+1
New +$29 ﹤0.01% 1115

Other funds holding IPXL

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wealthfront's IPXL Position: Q4 2015 in Review

Wealthfront sold out of Impax Laboratories, Inc. (IPXL) in Q4 2015, closing a stake of 215 shares — an estimated $8K sold.

Wealthfront first reported a position in IPXL in Q4 2014 and held it in 4 quarters. The position peaked at $12K in Q2 2015. 196 funds tracked by Wall St. Rank hold IPXL as of Q4 2015.

  • Wealthfront reported no remaining Impax Laboratories, Inc. position as of Q4 2015 after selling out during the quarter.
  • Wealthfront sold 215 Impax Laboratories, Inc. shares in Q4 2015, an estimated $8K.
  • Wealthfront first reported a position in Impax Laboratories, Inc. in Q4 2014 and held it in 4 quarters.
  • Wealthfront's Impax Laboratories, Inc. position peaked at $12K in Q2 2015.
  • 196 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2015.

Based on Wealthfront's 13F filing for Q4 2015, filed 17 Feb 2016.